Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of ajust™ in stress urinary incontinence

Conditions: Female Stress Urinary Incontinence

Summary: the purpose of this study is to assess the overall effectiveness of the ajust adjustable single-incision sling in the surgical treatment of female stress urinary incontinence.

urinary incontinence (ui), or the complaint of any involuntary loss of urine, ranges in severity from the occasional leaking urine during actions resulting in increased abdominal pressure (coughing, sneezing, laughing, exercise, etc.) to sudden, unpredictable strong urges to void. female stress urinary incontinence (sui) is attributed to a weakening of the pelvic floor muscles. a recent review of literature describing the prevalence of ui calculated the median prevalence of female ui to be 27.6% (4.8-58.4%), with the prevalence of significant incontinence increasing with age. the prevalent cause of ui was further categorized into stress (50%), mixed (32%) and urge (14%). nonsurgical treatment of female sui has traditionally been limited to alpha-adrenergic agonists and estrogens, pelvic floor exercises, biofeedback, electrical stimulation and behavior modification1. options for surgical treatment consists of periurethral injections of bulking agents, transvaginal suspensions, retropubic suspensions, slings and sphincter prostheses. the ajust™ adjustable single-incision sling is a fully adjustable single-incision sling that anchors in the transobturator membranes, anatomically sufficient spaces for support of the urethra.

Eligibility criteria:
inclusion criteria: * female, age at least 18 years * have signed an informed consent form * has been diagnosed with stress urinary incontinence as documented by: a minimum 30-degree urethral deflection, considered to be a candidate for transobturator repair by consulting surgeon (investigator), has a positive cst * desires surgical correction of sui using the ajust™ adjustable single-incision sling exclusion criteria: * patient is actively participating in any other genitourinary clinical trial of an experimental drug or device * patient is known to be pregnant or desiring future childbearing * patient has a known urinary tract infection, or known infection in the operative field at the time of device implantation * patient is unable to have their anticoagulation therapy suspended for the completion of the surgical procedure * patient requires concurrent correction of pelvic organ prolapse * patient has a history of previous sling procedure * patient has known history of detrusor overactivity demonstrated by urodynamics * patient has known urinary retention * patient has a current genitourinary fistula or urinary diverticulum * patient has a prior history of pelvic radiation * patient has a mesa urge symptom score (% of total possible urge score) that is greater than their mesa stress symptom score (% of total possible stress score) * any condition in the opinion of the investigator that would preclude the use of the ajust™ adjustable single-incision sling, or preclude the subject from completing the follow-up requirements
use of vibration to improve visual/spatial neglect in patients affected by stroke

Conditions: Unilateral Spatial Neglect

Summary: this study will measure if five minutes of vibration to the upper back neck muscles, prior to standard of care treatment, will improve symptoms of spatial neglect and/or activities of daily living function for patients who have had a stroke.

spatial neglect is a common syndrome following stroke, most frequently of the right side of the brain. such patients fail to be aware of objects or people to their left. this study is being done to learn if vibration treatment can improve visual/spatial neglect and activities of daily living in stroke patients better than current standard intervention.this treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.

Eligibility criteria:
inclusion criteria: * 18 years old or older * demonstrated visual/spatial neglect, as demonstrated by nih stroke scale (nihss) and deficits in assessing tactile extinction and visuospatial neglect done on admission. exclusion criteria: * severe pain or skin disease at the posterior neck * severe atherosclerosis of carotid arteries by an ultrasonic evaluation

Keywords: vibration stroke activities of daily living
ds-8201a in patients with cancer that tests positive for human epidermal growth factor receptor 2 (her2) protein

Conditions: Adenocarcinoma, Gastric; Neoplasm, Breast

Summary: her2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (her2). her2 promotes the growth of certain cancer cells. this study will test ds-8201a (trastuzumab deruxtecan), a her2-targeted antibody and topoisomerase i inhibitor conjugate. the safety and tolerability profile of ds-8201a will be assessed in chinese patients with certain types of stomach and breast cancer that test positive for her2. it also will test how ds-8201a moves within the body (pharmacokinetics).

the expected time from the first subject's enrollment until the last subject's enrollment is approximately 8 months. the screening period is 28 days and each cycle of treatment is 21 days. the number of treatment cycles is not fixed in this study. subjects who continue to derive clinical benefit from the study drug in the absence of withdrawal of consent, progressive disease (pd), or unacceptable toxicity may continue the study drug.

Eligibility criteria:
inclusion criteria: * has a pathologically documented unresectable or metastatic gastric or gej adenocarcinoma, or breast cancer, with her2 expression \[immunohistochemistry (ihc) 3+, 2+, or 1+ and/or in situ hybridization (ish) +\] that is refractory to or intolerable with standard treatment, or for which no standard treatment is available * has a left ventricular ejection fraction (lvef) ≥ 50% * has an eastern cooperative oncology group performance status (ecog ps) score of 0 or 1 exclusion criteria: * has a medical history of myocardial infarction within 6 months before enrollment * has a medical history of ventricular arrhythmias, other than rare occasional premature ventricular contractions * has uncontrolled or significant cardiovascular disease * has any other history or condition that might compromise: 1. safety of the participant or offspring 2. safety of study staff 3. analysis of results

Keywords: stomach cancer cancer where the esophagus meets the stomach human epidermal growth factor 2 her2 breast cancer adenocarcinoma, gastroesophageal junction (gej) gastric cancer antibody drug conjugate (adc) oncology
flipped learning in pph education: impact on midwifery students' knowledge, skills, self-efficacy, and satisfaction

Conditions: Teaching Innovation; Midwifery Students Education; Postpartum Hemorrhage; Flipped Classroom Model in Teaching

Summary: maternal death refers to a woman's death due to direct or indirect causes during pregnancy, childbirth, or within 42 days postpartum. postpartum hemorrhage (pph) is the leading cause of maternal mortality globally and in our country. rapid and effective management of pph is crucial in reducing maternal deaths. who, unfpa, and unicef emphasize the critical role of midwives in pph management, highlighting the importance of enhancing their knowledge and skills during pre-graduate education. traditional education models are often insufficient for fostering permanent learning, especially in acquiring psychomotor skills like pph management. in traditional learning, classroom instruction follows a teacher-centered approach, covering only the first two levels of bloom's taxonomy-knowledge and comprehension-while higher-order cognitive skills such as application, analysis, synthesis, and evaluation are left to individual effort. however, effective and lasting learning requires an active learning environment where students engage more deeply with the material. the flipped learning model addresses these challenges by allowing students to access foundational knowledge outside the classroom and dedicate class time to higher-order skills like discussion, application, and problem-solving. this model enhances learning through technology and interactive face-to-face activities, fostering professional competence in health education. while the flipped learning model is widely used in health education, most studies focus on theoretical knowledge, with limited research on psychomotor skill acquisition. to our knowledge, this study is the first to evaluate the effectiveness of flipped learning in midwifery education for both theoretical and psychomotor skill development. the findings are expected to contribute to advancements in midwifery education and healthcare services.


Eligibility criteria:
inclusion criteria: * being a 3rd year student in the midwifery department of gülhane health sciences faculty * having successfully completed the normal birth course * agreeing to participate in the study exclusion criteria: * students who were on sick leave or on sick leave during the study period * those who did not take the normal birth course or failed * students who were absent from at least one session of the training program

Keywords: flipped learning postpartum hemorrhage midwifery education clinical self-efficacy
sgo society of gynecologic oncologists data outcomes project

Conditions: Pelvic Tumor

Summary: sgo society of gynecologic oncologists data outcomes project.

examines data over period of time

Eligibility criteria:
inclusion criteria: 1. must have a pelvic mass with surgery taking place.

Keywords: pelvic mass
touching the world with a cane: cognitive and neural processes

Conditions: Visual Impairment; Healthy

Summary: the use of tools is ubiquitous in our lives and allows us to expand the sensorimotor capacities of our body. much research has been done on the subject in sighted people over the past decades. this work has mainly focused on the motor aspect of using the tool, neglecting the sensory aspect. however, any action involving a tool carries sensory information, for example in the use of the white cane by blind people. 26% (\> 200,000) of blind people in france use a white cane to get around. by sweeping the cane on the ground, they use it as a sensorimotor extension of their body to extract information from the environment in order to locate a pedestrian crossing or possible obstacles. while it is well established that the tools increase the user's motor skills, we have only just begun to clarify how they also function as sensory extensions of the user's body and how this phenomenon is potentially dependent on constant use of the tool to compensate for a missing sense, as is the case with blind people using a cane. the aim of this study is to fill this important gap in our knowledge.


Eligibility criteria:
inclusion criteria: * man or woman, aged 18 to 60 years old * give an informed consent by signature * be part of the national health security system (registered to the securité sociale) * do not confuse his right and his left specific of the non-sighted participants: * loss of vision happened at birth or 3-to 5 years later in life * must have a visual acuity inferior or equal to 4/10 * be with a close relation for read information letter and sign the consent form if needed exclusion criteria: * a person presenting an history of neurological, psychiatric or linguistic problems cannot be admitted * assumption of psychotropic drugs * pregnancy or breast-feeding woman * a person under legal tutoring * a person under care in other medical structure for reasons different from those of this research * a person under administrative or judiciary contention * a person who is not eligible to a mri-exam according to the following criteria cannot be admitted to the experiments including mr acquisitions : * have a neurological, cardiac (battery) or defibrillator pacemaker * have a cardiac prosthesis (valve, stent...) or vascular prosthesis * have intracranial clips or clamps * carry a bypass of the cerebrospinal fluid * having metallic splinters in the eyes * wear metal prostheses (teeth, knees) * wear an infusion pump or system * be claustrophobic or have respiratory problems * have metal tattoos close to the head * have permanent make-up

Keywords: blind/non-sighted healthy subject fmri eeg
liquid biospy for urinary cancers

Conditions: Urothelial Carcinoma

Summary: the project aims to characterize the prognostic role of ctcs in bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by ctcs.

bladder cancer (bca) is the 9th most common cancer worldwide, with an estimated prevalence of around 2.7 million cases and an incidence around 350.000 new cases/year. the proper management of bca remains an unmet clinical need, because one of the main problems in bca treatment is the inability to efficaciously prevent high-grade non-muscle invasive bladder cancer (nmibc) relapse and progression, which occur in 80% and 45% of patients respectively. indeed, as a consequence of the lack of efficient established prognostic, diagnostic and predictive biomarker of high-risk nmibc, bca patients undergo multiple treatments and cystoscopic assessments along their life, with consequent poor quality of life and high healthcare costs. circulating tumor cells (ctcs) in blood represent an invaluable source of tumor material that can be easily collected yhrough a simple blood draw and may represent the clonal component of the primary tumor that left the primary site. for this reason, the aim of this study is to characterize the prognostic role of ctcs in bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by ctcs.

Eligibility criteria:
inclusion criteria: diagnosis of urothelial neoplasia, naive for therapy exclusion criteria: absence of previous neolpastic disease or genetic diseases
evaluate the efficacy and safety of serplulimab plus chemotherapy in neoadjuvant and adjuvant treatment of resectable nsclc (ectop-1013)

Conditions: Non-small Cell Lung Cancer; Stage II-IIIA; Immunotherapy; Neoadjuvant Therapy

Summary: this is a clinical trial from eastern cooperative thoracic oncology project (ectop), numbered as ectop-1013. the purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of serplulimab and chemotherapy in treating resectable non-small cell lung cancer(nsclc).


Eligibility criteria:
inclusion criteria: * stage ib-iiia, operable non-small cell lung cancer, confirmed in tissue. * able and willing to give written informed consent and has signed the informed consent form (icf), prior to performance of any trial activities. * eligible male and female subjects aged 18-75 years. * lung function capacity capable of tolerating the proposed lung surgery. * eastern cooperative oncology group (ecog) performance status of 0-1. * available tissue of primary lung tumor. exclusion criteria: * presence of locally advanced, inoperable or metastatic disease. * subjects with egfr mutation or alk、ros1 gene rearrangement. * participants with active, known or suspected autoimmune disease. * prior treatment with any drug that targets t cell co-stimulations pathways (such as checkpoint inhibitors). other protocol defined inclusion/exclusion criteria apply
diagnostic of chronic thrombocytopenia

Conditions: Congenital Thrombocytopenia; Chronic Idiopathic Thrombocytopenic Purpura

Summary: the objective of this study is to provide simple and relevant clinical and biological elements to distinguish a possible congenital thrombocytopenia from a chronic idiopathic thrombocytopenic purpura .

congenital thrombocytopenia is a group of rare diseases, often unrecognized and misdiagnosed as chronic idiopathic thrombocytopenic purpura. these chronic idiopathic thrombocytopenic purpura, which are exclusion diagnoses, are most often treated with corticosteroids or intravenous immunoglobulins and sometimes, when thrombocytopenia is refractory, splenectomy is performed. currently, it is often before a case of thrombocytopenia refractory to the treatment of the dysimmunity syndrome that the notion of congenital thrombocytopenia is evoked. the percentage of false diagnoses (misdiagnosed chronic idiopathic thrombocytopenic purpura diagnoses) seems to represent to date 10 to 20% of cases. the objective of this study is to provide simple and relevant clinical and biological elements to distinguish a possible congenital thrombocytopenia from a chronic idiopathic thrombocytopenic purpura.

Eligibility criteria:
inclusion criteria: * all patients with chronic thrombocytopenia (\> 6 months) between 10 and 150 g / l, regardless of age or gender, * subjects with a definite chronic idiopathic thrombocytopenic purpuras, - subjects with a certain degree of certainty, sometimes pre-identified and already known at the level of the c reactive protein, * subjects with chronic thrombocytopenia of undetermined origin, not definitively entering one of the 2 groups mentioned above. exclusion criteria: * thrombocytopenia less than 6 months old; * patients with thrombocytopenia related to a viral or chronic infectious pathology (hiv infections or hepatitis c virus, bacterial infections with helicobacter pillory, for example), an autoimmune disease, in particular systemic lupus and / or antiphospholipid syndrome, a bleeding disorder such as a intra-vascular disseminated coagulation, thrombotic microangiopathy, hypersplenism, a responsible medication intake, myelodysplastic syndrome, a pregnancy in progress. * patients should not be treated with immunoglobulin iv, rituximab or anti-cd20 less than 30 days before the date of collection.
tenofovir-df versus hydroxychloroquine in the treatment of hospitalized patients with covid-19 (tedhicov)

Conditions: Covid19; SARS-CoV Infection; Tenofovir

Summary: although several therapeutic agents have been suggested for the treatment of the disease caused by the coronavirus of the year 2019 (covid-19), no antiviral has yet demonstrated consistent efficacy. this is an observational study comparing tenofovir-df (disoproxil fumarate) (tdf) with hydroxychloroquine (hcq) in the treatment of hospitalized patients with covid-19 with evidence of pulmonary compromise and with supplemental oxygen required.

all hospitalized patients with covid-19 from march 2020 to may 30, 2020 at the "hospital nacional carlos alberto seguín escobedo (case)-essalud" (arequipa, peru) with a pcr-confirmed diagnosis of sars-cov-2 will be included. the primary outcomes to be compared will be mortality, the need for admission to the intensive care unit (icu) and / or mechanical ventilation, and los (length of stay) in both groups. furthermore, demographic factors, risk factors, vital / respiratory functions, and laboratory results of both groups will be compared. the tests closest to the time of admission to the hospital will be taken into consideration. statistical analysis: quantitative variables will be expressed as mean ± standard deviation, qualitative variables will be expressed as percentages (%). in the univariate analysis, the student's t test will be used for the means and the chi2 test for nominal or ordinal variables. kaplan-meier survival curves will be evaluated 30 days after admission to the hospital to assess mortality. the multivariate analysis of the variables that result significant in the univariate analysis will be carried out by the cox regression model in the evaluation of mortality; the multivariate linear regression model for the evaluation of the stay and the "log rank" model for the evaluation of admission to the intensive care unit (icu) or the need for mechanical ventilation (mv). in addition, models will be developed to estimate the effects of tdf treatment by regression adjustment for the primary outcomes of this observational study: hospital stay, need for icu (intensive care unit) and / or mv (mechanical ventilation) and mortality. the stata® software version 14 will be used and p \<o.o5 will be considered significant.

Eligibility criteria:
inclusion criteria: * hospitalized adults over 18 years of age * positive molecular test for sars-cov-2 * computed tomography (tc scan) compatible with "covid pneumonia" and / or in need of supplemental oxygen * therapy with tenofovir-df (tdf) or hydroxychloroquine (hcq) at least 3 days * signed informed consent exclusion criteria: * negative molecular test for sars-cov-2 * no need for hospitalization * negative ct scan for "covid pneumonia" and / or no supplemental oxygen requirement for covid-19 * had not received either hcq or tdf, or both drugs at the same time, or had received hcq or tdf for two days or less * no signed informed consent

Keywords: covid-19 sars-cov-2 tenofovir hydroxychloroquine hospitalized
remifentanil in children with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this investigation tested the hypothesis that children with obstructive sleep apnea have an increased pharmacodynamic sensitivity to the miotic and respiratory depressant effects of the prototypic μ-opioid agonist remifentanil.


Eligibility criteria:
osa group: inclusion criteria: * 8-14 years old * asa physical status 1 or 2 * undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea exclusion criteria: * inability to cooperate with study requirements (iv placement, sitting quietly, wearing goggles, etc.) control (non-osa) group: inclusion criteria: * 8-14 years old * asa physical status 1 or 2 * no known obstructive sleep apnea presenting for any procedure requiring general anesthtic exclusion criteria: * inability to cooperate with study requirements (iv placement, sitting quietly, wearing goggles, etc.)
impact of respiratory muscle unloading on respiratory muscle endurance

Conditions: Chronic Respiratory Failure

Summary: this study investigates how different degrees of muscular unloading during mechanical ventilation impact endurance of succeeding spontaneous breathing trials

liberation from mechanical ventilation in difficult to wean patients is best accomplished by intermittent spontaneous breathing trials (1). optimal respiratory muscle rest in-between breathing trials however has never been investigated. using a crossover design, patients are to be ventilated with complete and partial respiratory muscle unloading for a period of ten hours respectively. respiratory muscle activity is being monitored by oesophageal balloon technique using a commercially available system (avea, viasys, conshohocken, pa, usa). time of spontaneous breathing, respiratory- and abg parameters are being determined to characterize the course of each spontaneous breathing trial. references 1. esteban, a., f. frutos, m. j. tobin, i. alia, j. f. solsona, i. valverdu, r. fernandez, m. a. de la cal, s. benito, r. tomas, and et al. 1995. a comparison of four methods of weaning patients from mechanical ventilation. spanish lung failure collaborative group. n engl j med 332(6):345-50.

Eligibility criteria:
inclusion criteria: * hypercapnic respiratory failure exclusion criteria: * upper gi pathology * renal failure (creatinin \> 2 mg/dl) * sepsis or infection * age \< 18 years

Keywords: weaning work of breathing spontaneous breathing trial rapid shallow breathing